Financing, Equity Capital Markets

Revance Therapeutics, Inc.

01/19
|
$115.0 Million
Piper Sandler served as bookrunner for Revance Therapeutics, Inc. on a follow-on offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma